托法替布治疗溃疡性结肠炎的全球上市后安全性监测经验
该研究分析了2018年5月30日至2020年8月25日全球托法替布上市后安全性数据库中的报告,暴露量估计为8916患者年。关注的特殊严重不良事件报告率(每100患者年)为:感染3.28、血管疾病1.26、呼吸疾病0.74、肿瘤0.55、心脏疾病0.50。不良事件类型与临床试验报告一致,大多数为非严重不良事件。
要点
- 全球上市后监测显示托法替布治疗UC的不良事件类型与临床试验一致。
- 严重不良事件报告率:感染3.28/100患者年,血管疾病1.26/100患者年。
- 大多数报告的不良事件为非严重事件,致命性事件占0.4%。
核心结论
- 托法替布治疗溃疡性结肠炎的上市后不良事件类型与临床试验报告一致,大多数不良事件为非严重事件。
研究设计与样本
- 分析辉瑞安全性数据库中2018年5月30日至2020年8月25日全球托法替布上市后监测报告,暴露量基于全球销售数据和每日方案估算为8916患者年。
主要发现
- 1141例(27.0%)报告包含严重不良事件,18例(0.4%)为致命性。
- 关注的特殊严重不良事件报告率(每100患者年):感染3.28,血管疾病1.26,呼吸疾病0.74,肿瘤0.55,心脏疾病0.50。
临床怎么用
- 临床医生应了解托法替布治疗UC的上市后安全性特征,关注感染、血管疾病等严重不良事件。
局限性
- 上市后监测报告存在局限性,且暴露量缺乏精确值,报告率仅为估算值,解读结果时应考虑这些因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor for the treatment of ulcerative colitis (UC). Post-marketing surveillance (PMS) is an important part of monitoring adverse events (AEs). AIMS: To report an analysis of PMS case safety reports for tofacitinib in patients with UC METHODS: Worldwide tofacitinib PMS reports received in the Pfizer safety database from 30 May 2018 (first regulatory approval) to 25 August 2020 were analysed. The type and estimated reporting rate (RR) of serious AEs of interest, including infection, gastrointestinal, vascular, respiratory, neoplasm and cardiac events, were reviewed. Patient-years of exposure (PY) was estimated based on worldwide sales data and the calculated daily regimens of tofacitinib 5 or 10 mg twice daily, immediate- or extended-release formulations. RESULTS: During the 27-month reporting period, worldwide post-marketing exposure to tofacitinib was 8916 PY. Overall, 4226 case reports were received and included 12 103 AEs, of which 1839 were serious AEs (SAEs). Among the cases reported, 1141 (27.0%) included an SAE and 18 (0.4%) were fatal. The RR (per 100 PY) for SAEs of interest by Medical Dictionary for Regulatory Activities System Organ Class were 3.28 for infections, 1.26 for vascular disorders, 0.74 for respiratory disorders, 0.55 for neoplasms and 0.50 for cardiac disorders. CONCLUSIONS: The types of AEs were consistent with those reported in tofacitinib clinical trials. Most reported AEs were non-serious. Limitations of PMS reports and reliance on estimated RRs due to lack of precise values for exposure, required for incidence rate calculation, should be considered when interpreting these results.
引用
- Rubin DT, Modesto I, Vermeire S, et al. Worldwide post-marketing safety surveillance experience with tofacitinib in ulcerative colitis. Aliment Pharmacol Ther. 2021. PMID: 34626429. doi:10.1111/apt.16619
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。